Cancer research最新文献_第5页

Pancreatic Cancer-Associated Fibroblasts: Where Do We Go from Here? 胰腺癌相关成纤维细胞：何去何从？

IF 12.5 1区医学

Cancer research Pub Date : 2024-11-04 DOI: 10.1158/0008-5472.CAN-24-2860

Eileen S Carpenter, Debora Barbosa Vendramini-Costa, Marie C Hasselluhn, Anirban Maitra, Kenneth P Olive, Edna Cukierman, Marina Pasca di Magliano, Mara H Sherman

引用次数: 0

Editor's Note: Multiple Injections of Electroporated Autologous T Cells Expressing a Chimeric Antigen Receptor Mediate Regression of Human Disseminated Tumor. 编者按：多次注射表达嵌合抗原受体的电穿孔自体 T 细胞可促进人类播散性肿瘤的消退。

IF 12.5 1区医学

Cancer research Pub Date : 2024-11-04 DOI: 10.1158/0008-5472.CAN-24-2930

Yangbing Zhao, Edmund Moon, Carmine Carpenito, Chrystal M Paulos, Xiaojun Liu, Andrea L Brennan, Anne Chew, Richard G Carroll, John Scholler, Bruce L Levine, Steven M Albelda, Carl H June

引用次数: 0

PHGDH Induction by MAPK is Essential for Melanoma Formation and Creates an Actionable Metabolic Vulnerability. MAPK 对 PHGDH 的诱导是黑色素瘤形成的必要条件，并产生了可操作的代谢脆弱性。

IF 12.5 1区医学

Cancer research Pub Date : 2024-11-04 DOI: 10.1158/0008-5472.CAN-24-2471

Neel Jasani, Xiaonan Xu, Benjamin Posorske, Yumi Kim, Kaizhen Wang, Olga Vera, Kenneth Y Tsai, Gina M DeNicola, Florian A Karreth

{"title":"PHGDH Induction by MAPK is Essential for Melanoma Formation and Creates an Actionable Metabolic Vulnerability.","authors":"Neel Jasani, Xiaonan Xu, Benjamin Posorske, Yumi Kim, Kaizhen Wang, Olga Vera, Kenneth Y Tsai, Gina M DeNicola, Florian A Karreth","doi":"10.1158/0008-5472.CAN-24-2471","DOIUrl":"10.1158/0008-5472.CAN-24-2471","url":null,"abstract":"Overexpression of PHGDH, the rate-limiting enzyme in the serine synthesis pathway, promotes melanomagenesis, melanoma cell proliferation, and survival of metastases in serine-low environments such as the brain. Here, we found that PHGDH is universally increased in melanoma cells and required for melanomagenesis. While PHGDH amplification explained PHGDH overexpression in a subset of melanomas, oncogenic BRAFV600E also promoted PHGDH transcription through mTORC1-mediated translation of ATF4. Importantly, depletion of PHGDH in genetic mouse melanoma models blocked tumor formation. In addition to BRAFV600E-mediated upregulation, PHGDH was further induced by exogenous serine restriction. Surprisingly, BRAFV600E inhibition diminished serine restriction-mediated PHGDH expression by preventing ATF4 induction. Consequently, melanoma cells could be specifically starved of serine by combining BRAFV600E inhibition with exogenous serine restriction, which promoted cell death in vitro and attenuated melanoma growth in vivo. In summary, this study identified that PHGDH is essential for melanomagenesis and regulated by BRAFV600E, revealing a targetable vulnerability in BRAFV600E-mutant melanoma.","PeriodicalId":9441,"journal":{"name":"Cancer research","volume":" ","pages":""},"PeriodicalIF":12.5,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142566488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

ACE2 Enhances Sensitivity to PD-L1 Blockade by Inhibiting Macrophage-Induced Immunosuppression and Angiogenesis. ACE2 通过抑制巨噬细胞诱导的免疫抑制和血管生成增强对 PD-L1 阻断剂的敏感性

IF 12.5 1区医学

Cancer research Pub Date : 2024-11-04 DOI: 10.1158/0008-5472.CAN-24-0954

Peiyi Xie, Lei Guo, Qiang Yu, Yufei Zhao, Mincheng Yu, Hui Wang, Mengyuan Wu, Wenxin Xu, Min Xu, Xiao-Dong Zhu, Yongfeng Xu, Yong-Sheng Xiao, Cheng Huang, Jian Zhou, Jia Fan, Mien-Chie Hung, Huichuan Sun, Qing-Hai Ye, Bo Zhang, Hui Li

{"title":"ACE2 Enhances Sensitivity to PD-L1 Blockade by Inhibiting Macrophage-Induced Immunosuppression and Angiogenesis.","authors":"Peiyi Xie, Lei Guo, Qiang Yu, Yufei Zhao, Mincheng Yu, Hui Wang, Mengyuan Wu, Wenxin Xu, Min Xu, Xiao-Dong Zhu, Yongfeng Xu, Yong-Sheng Xiao, Cheng Huang, Jian Zhou, Jia Fan, Mien-Chie Hung, Huichuan Sun, Qing-Hai Ye, Bo Zhang, Hui Li","doi":"10.1158/0008-5472.CAN-24-0954","DOIUrl":"https://doi.org/10.1158/0008-5472.CAN-24-0954","url":null,"abstract":"Anti-PD-L1-based combination immunotherapy has become the first-line treatment for unresectable hepatocellular carcinoma (HCC). However, the objective response rate is lower than 40%, highlighting the need to identify mechanisms of tolerance to immune checkpoint inhibitors and accurate biomarkers of response. Here, we employed next-generation sequencing to analyze HCC samples from 10 patients receiving anti-PD-L1 therapy. Activation of the renin-angiotensin system was elevated in nonresponders compared with responders, and ACE2 expression was significantly downregulated in nonresponders. ACE2 deficiency promoted HCC development and anti-PD-L1 resistance, whereas ACE2 overexpression inhibited HCC progression in immune competent mice. Mass cytometry by time of flight (CyTOF) revealed that ACE2 deficient murine orthotopic tumor tissues featured elevated M2-like tumor-associated macrophages (TAMs), displayed a CCR5+PD-L1+ immunosuppressive phenotype, and exhibited high VEGFα expression. ACE2 downregulated tumor intrinsic CCL5 expression by suppressing NF-κB signaling through the ACE2/angiotensin-(1-7)/Mas receptor axis. The lower CCL5 levels led to reduced activation of the JAK-STAT3 pathway and suppressed PD-L1 and VEGFα expression in macrophages, blocking macrophage infiltration and M2-like polarization. Pharmacological targeting of CCR5 using maraviroc enhanced the tumor suppressive effect of anti-PD-L1 therapy. Together, these findings suggest that activation of the ACE2 axis overcomes the immunosuppressive microenvironment of HCC and may serve as an immunotherapeutic target and predictive biomarker of response to PD-L1 blockade.","PeriodicalId":9441,"journal":{"name":"Cancer research","volume":" ","pages":""},"PeriodicalIF":12.5,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142566331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Pan-Tumor Vasculature under the Transcriptomic Magnifying Glass. 转录组放大镜下的泛肿瘤血管

IF 12.5 1区医学

Cancer research Pub Date : 2024-11-04 DOI: 10.1158/0008-5472.CAN-24-3219

Krish Skandha Gopalan, Gabriele Bergers

引用次数: 0

H4K20me3-Mediated Repression of Inflammatory Genes is a Characteristic and Targetable Vulnerability of Persister Cancer Cells. H4K20me3 介导的炎症基因抑制是顽固性癌细胞的一个特征性弱点，也是可瞄准的弱点。

IF 12.5 1区医学

Cancer research Pub Date : 2024-10-30 DOI: 10.1158/0008-5472.CAN-24-0529

Valentina Ramponi, Laia Richart, Marta Kovatcheva, Camille Stephan-Otto Attolini, Jordi Capellades, Alice E Lord, Oscar Yanes, Gabriella Ficz, Manuel Serrano

{"title":"H4K20me3-Mediated Repression of Inflammatory Genes is a Characteristic and Targetable Vulnerability of Persister Cancer Cells.","authors":"Valentina Ramponi, Laia Richart, Marta Kovatcheva, Camille Stephan-Otto Attolini, Jordi Capellades, Alice E Lord, Oscar Yanes, Gabriella Ficz, Manuel Serrano","doi":"10.1158/0008-5472.CAN-24-0529","DOIUrl":"https://doi.org/10.1158/0008-5472.CAN-24-0529","url":null,"abstract":"Anti-cancer therapies can induce cellular senescence, which is highly stable, or drug-tolerant persistence, which is efficiently reversed upon therapy termination. While approaches to target senescent cells have been extensively studied, further understanding of the processes regulating persistence is needed to develop treatment strategies to suppress persister cell survival. Here, we used mTOR/PI3K inhibition to develop and characterize a model of persistence-associated arrest in human cancer cells of various origins. Persister and senescent cancer cells shared an expanded lysosomal compartment and hypersensitivity to BCL-XL inhibition. However, persister cells lacked other features of senescence, such as loss of lamin B1, senescence-associated β-galactosidase activity, upregulation of MHC-I, and an inflammatory and secretory phenotype (SASP). Genome-wide CRISPR/Cas9 screening for genes required for the survival of persister cells revealed that they are hypersensitive to the inhibition of one-carbon (1C) metabolism, which was validated by the pharmacological inhibition of SHMT, a key enzyme that feeds methyl groups from serine into 1C metabolism. Connecting 1C metabolism with the epigenetic regulation of transcription, the repressive heterochromatic mark H4K20me3 was enriched at the promoters of SASP and interferon response genes in persister cells, while it was absent in proliferative or senescent cells. Moreover, persister cells overexpressed the H4K20 methyltransferases KMT5B/C, and their downregulation unleashed inflammatory programs and compromised the survival of persister cells. In summary, this study defined distinctive features of persister cancer cells, identified actionable vulnerabilities, and provided mechanistic insight into their low inflammatory activity.","PeriodicalId":9441,"journal":{"name":"Cancer research","volume":" ","pages":""},"PeriodicalIF":12.5,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142543885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacological blockade of a pioneer transcription factor. 药理阻断先锋转录因子。

IF 12.5 1区医学

Cancer research Pub Date : 2024-10-30 DOI: 10.1158/0008-5472.CAN-24-3957

Katerina Cermakova, H Courtney Hodges

引用次数: 0

The Functional Transcriptomic Landscape Informs Therapeutic Strategies in Multiple Myeloma. 功能转录组格局为多发性骨髓瘤治疗策略提供依据

IF 12.5 1区医学

Cancer research Pub Date : 2024-10-30 DOI: 10.1158/0008-5472.CAN-24-0886

Praneeth Reddy Sudalagunta, Rafael R Canevarolo, Mark B Meads, Maria Silva, Xiaohong Zhao, Christopher L Cubitt, Samer S Sansil, Gabriel DeAvila, Raghunandan Reddy Alugubelli, Ryan T Bishop, Alexandre Tungesvik, Qi Zhang, Oliver Hampton, Jamie K Teer, Eric A Welsh, Sean J Yoder, Bijal D Shah, Lori Hazlehurst, Robert A Gatenby, Dane R Van Domelen, Yi Chai, Feng Wang, Andrew DeCastro, Amanda M Bloomer, Erin M Siegel, Conor C Lynch, Daniel M Sullivan, Melissa Alsina, Taiga Nishihori, Jason Brayer, John L Cleveland, William Dalton, Christopher J Walker, Yosef Landesman, Rachid Baz, Ariosto S Silva, Kenneth H Shain

{"title":"The Functional Transcriptomic Landscape Informs Therapeutic Strategies in Multiple Myeloma.","authors":"Praneeth Reddy Sudalagunta, Rafael R Canevarolo, Mark B Meads, Maria Silva, Xiaohong Zhao, Christopher L Cubitt, Samer S Sansil, Gabriel DeAvila, Raghunandan Reddy Alugubelli, Ryan T Bishop, Alexandre Tungesvik, Qi Zhang, Oliver Hampton, Jamie K Teer, Eric A Welsh, Sean J Yoder, Bijal D Shah, Lori Hazlehurst, Robert A Gatenby, Dane R Van Domelen, Yi Chai, Feng Wang, Andrew DeCastro, Amanda M Bloomer, Erin M Siegel, Conor C Lynch, Daniel M Sullivan, Melissa Alsina, Taiga Nishihori, Jason Brayer, John L Cleveland, William Dalton, Christopher J Walker, Yosef Landesman, Rachid Baz, Ariosto S Silva, Kenneth H Shain","doi":"10.1158/0008-5472.CAN-24-0886","DOIUrl":"https://doi.org/10.1158/0008-5472.CAN-24-0886","url":null,"abstract":"Several therapeutic agents have been approved for treating multiple myeloma (MM), a cancer of bone marrow resident plasma cells. Predictive biomarkers for drug response could help guide clinical strategies to optimize outcomes. Here, we present an integrated functional genomic analysis of tumor samples from MM patients that were assessed for their ex vivo drug sensitivity to 37 drugs, clinical variables, cytogenetics, mutational profiles, and transcriptomes. This analysis revealed a MM transcriptomic topology that generates \"footprints\" in association with ex vivo drug sensitivity that have both predictive and mechanistic applications. Validation of the transcriptomic footprints for the anti-CD38 monoclonal antibody daratumumab and the nuclear export inhibitor selinexor demonstrated that these footprints can accurately classify clinical responses. The analysis further revealed that daratumumab and selinexor have anti-correlated mechanisms of resistance, and treatment with a selinexor-based regimen immediately after a daratumumab-containing regimen was associated with improved survival in three independent clinical trials, supporting an evolutionary-based strategy involving sequential therapy. These findings suggest that this unique repository and computational framework can be leveraged to inform underlying biology and to identify therapeutic strategies to improve treatment of MM.","PeriodicalId":9441,"journal":{"name":"Cancer research","volume":" ","pages":""},"PeriodicalIF":12.5,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142543887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

SOS1 Inhibition Enhances the Efficacy of KRASG12C Inhibitors and Delays Resistance in Lung Adenocarcinoma 抑制 SOS1 可增强 KRASG12C 抑制剂的疗效并延缓肺腺癌的耐药性

IF 11.2 1区医学

Cancer research Pub Date : 2024-10-22 DOI: 10.1158/0008-5472.can-23-3256

Brianna R. Daley, Nancy E. Sealover, Bridget A. Finniff, Jacob M. Hughes, Erin Sheffels, Daniel Gerlach, Marco H. Hofmann, Kaja Kostyrko, Joseph P. LaMorte, Amanda Linke, Zaria Beckley, Andrew M. Frank, Robert E. Lewis, Matthew D. Wilkerson, Clifton Dalgard, Robert L. Kortum

{"title":"SOS1 Inhibition Enhances the Efficacy of KRASG12C Inhibitors and Delays Resistance in Lung Adenocarcinoma","authors":"Brianna R. Daley, Nancy E. Sealover, Bridget A. Finniff, Jacob M. Hughes, Erin Sheffels, Daniel Gerlach, Marco H. Hofmann, Kaja Kostyrko, Joseph P. LaMorte, Amanda Linke, Zaria Beckley, Andrew M. Frank, Robert E. Lewis, Matthew D. Wilkerson, Clifton Dalgard, Robert L. Kortum","doi":"10.1158/0008-5472.can-23-3256","DOIUrl":"https://doi.org/10.1158/0008-5472.can-23-3256","url":null,"abstract":"The clinical effectiveness of KRASG12C inhibitors (G12Ci) is limited both by intrinsic and acquired resistance, necessitating the development of combination approaches. Here, we identified targeting proximal receptor tyrosine kinase (RTK) signaling using the SOS1 inhibitor (SOS1i) BI-3406 as a strategy to improve responses to G12Ci treatment. SOS1i enhanced the efficacy of G12Ci and limited rebound RTK/ERK signaling to overcome intrinsic/adaptive resistance, but this effect was modulated by SOS2 protein levels. G12Ci drug tolerant persister (DTP) cells showed up to a 3-fold enrichment of tumor initiating cells (TIC), suggestive of a sanctuary population of G12Ci resistant cells. SOS1i re-sensitized DTPs to G12Ci and inhibited G12C-induced TIC enrichment. Co-mutation of the tumor suppressor KEAP1 limited the clinical effectiveness of G12Ci, and KEAP1 and STK11 deletion increased TIC frequency and accelerated the development of acquired resistance to G12Ci, consistent with clinical G12Ci resistance seen with these co-mutations. Treatment with SOS1i both delayed acquired G12Ci resistance and limited the total number of resistant colonies regardless of KEAP1 and STK11 mutational status. Together, these data suggest that targeting SOS1 could be an effective strategy to both enhance G12Ci efficacy and prevent G12Ci resistance regardless of co-mutations.","PeriodicalId":9441,"journal":{"name":"Cancer research","volume":"2 1","pages":""},"PeriodicalIF":11.2,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142487420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeted Degradation of SOS1 Exhibits Potent Anticancer Activity and Overcomes Resistance in KRAS-Mutant Tumors and BCR-ABL-Positive Leukemia 靶向降解 SOS1 在 KRAS 突变肿瘤和 BCR-ABL 阳性白血病中显示出强大的抗癌活性并克服抗药性

IF 11.2 1区医学

Cancer research Pub Date : 2024-10-22 DOI: 10.1158/0008-5472.can-24-1093

Ziwei Luo, Chencen Lin, Chuwei Yu, Changxian Yuan, Wenyong Wu, Xiaowei Xu, Renhong Sun, Yan Jia, yafang wang, Jie Shen, Dingyan Wang, Sinan Wang, Hualiang Jiang, Biao Jiang, Xiaobao Yang, Chengying Xie

{"title":"Targeted Degradation of SOS1 Exhibits Potent Anticancer Activity and Overcomes Resistance in KRAS-Mutant Tumors and BCR-ABL-Positive Leukemia","authors":"Ziwei Luo, Chencen Lin, Chuwei Yu, Changxian Yuan, Wenyong Wu, Xiaowei Xu, Renhong Sun, Yan Jia, yafang wang, Jie Shen, Dingyan Wang, Sinan Wang, Hualiang Jiang, Biao Jiang, Xiaobao Yang, Chengying Xie","doi":"10.1158/0008-5472.can-24-1093","DOIUrl":"https://doi.org/10.1158/0008-5472.can-24-1093","url":null,"abstract":"SOS1 is an essential guanine nucleotide exchange factor for RAS that also plays a critical role in the activation of the small GTPase RAC mediated by BCR-ABL in leukemogenesis. Despite this, small molecule inhibitors targeting SOS1 have shown limited efficacy in clinical trials for KRAS mutant cancers, and their potential as a therapeutic approach for chronic myeloid leukemia (CML) remains largely unexplored. In this study, we developed a potent SOS1 PROTAC SIAIS562055, which was designed by connecting a CRBN ligand to an analogue of the SOS1 inhibitor BI-3406. SIAIS562055 exhibited sustained degradation of SOS1 and inhibition of downstream ERK pathways, resulting in superior anti-proliferative activity compared to small molecule inhibitors. SIAIS562055 also potentiated the activity of both KRAS inhibitors in KRAS-mutant cancers and ABL inhibitors in BCR-ABL+ CML. In KRAS-mutant xenografts, SIAIS562055 displayed promising antitumor potency as a monotherapy and enhanced ERK inhibition and tumor regression when combined with KRAS inhibitors, overcoming acquired resistance. In CML cells, SIAIS562055 promoted the active uptake of BCR-ABL inhibitors by upregulating the carnitine/organic cation transporter SLC22A4. SIAIS562055 and BCR-ABL inhibitors synergistically enhanced inhibition of ABL phosphorylation and downstream signaling, demonstrating robust antitumor activities in both mouse xenografts and primary CML patient samples. In summary, this study suggests that PROTAC-mediated SOS1 degradation represents an eﬀective therapeutic strategy for treating not only KRAS-mutant cancers but also BCR-ABL-harboring leukemia.","PeriodicalId":9441,"journal":{"name":"Cancer research","volume":"79 1","pages":""},"PeriodicalIF":11.2,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142487506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0